M. Soty, A. Gautier-stein, and F. Rajas, Gut-brain glucose signaling in energy homeostasis, Cell Metab, vol.25, pp.1231-1242, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02339600

S. Kanungo, K. Wells, and T. Tribett, Glycogen metabolism and glycogen storage disorders, Ann Transl Med, vol.6, p.474, 2018.

M. A. Chen and D. A. Weinstein, Glycogen storage diseases: diagnosis, treatment and outcome, Transl Sci Rare Dis, vol.1, pp.45-72, 2016.

P. Burda and M. Hochuli, Hepatic glycogen storage disorders: what have we learned in recent years?, Curr Opin Clin Nutr Metab Care, vol.18, pp.415-421, 2015.

R. Godfrey and R. Quinlivan, Skeletal muscle disorders of glycogenolysis and glycolysis, Nat Rev Neurol, vol.12, pp.393-402, 2016.

N. Bruni, F. Rajas, and S. Montano, Enzymatic characterization of four new mutations in the glucose-6 phosphatase (G6PC) gene which cause glycogen storage disease type 1a, Ann Hum Genet, vol.63, pp.141-146, 1999.

F. Chevalier-porst, D. Bozon, and A. M. Bonardot, Mutation analysis in 24 French patients with glycogen storage disease type 1a, J Med Genet, vol.33, pp.358-360, 1996.

R. Froissart, M. Piraud, and A. M. Boudjemline, Glucose-6-phosphatase deficiency, Orphanet J Rare Dis, vol.6, p.27, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00668423

P. S. Kishnani, S. L. Austin, and J. E. Abdenur, Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics, Genet Med, vol.16, p.1, 2014.

M. Gjorgjieva, J. Calderaro, and L. Monteillet, Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia, J Hepatol, vol.69, pp.1074-1087, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02339527

M. Gjorgjieva, M. Raffin, and A. Duchampt, Progressive development of renal cysts in glycogen storage disease type I, Hum Mol Genet, vol.25, pp.3784-3797, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02339729

M. Gjorgjieva, M. H. Oosterveer, and G. Mithieux, Mechanisms by which metabolic reprogramming in GSD1 liver generates a favorable tumorigenic environment, J Inborn Errors Metab Screen, vol.4, pp.1-10, 2016.

J. Clar, B. Gri, and J. Calderaro, Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy, Kidney Int, vol.86, pp.747-756, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01350891

L. Monteillet, M. Gjorgjieva, and M. Silva, Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context, Mol Metab, vol.16, pp.100-115, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02339561

T. Steunenberg, F. Peeks, and I. J. Hoogeveen, Safety issues associated with dietary management in patients with hepatic glycogen storage disease, Mol Genet Metab, vol.125, pp.79-85, 2018.

M. Dambska, E. B. Labrador, and C. L. Kuo, Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control, Pediatr Diabetes, vol.18, pp.327-331, 2017.

G. O. Okechuku, L. R. Shoemaker, and M. Dambska, Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy, J Inherit Metab Dis, vol.40, pp.703-708, 2017.

R. D. Beegle, L. M. Brown, and D. A. Weinstein, Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I, JIMD Rep, vol.18, pp.23-32, 2015.

D. Q. Wang, L. M. Fiske, and C. T. Carreras, Natural history of hepatocellular adenoma formation in glycogen storage disease type I, J Pediatr, vol.159, pp.442-446, 2011.

D. Melis, M. Cozzolino, and G. Minopoli, Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study, J Pediatr, vol.166, pp.1079-1082, 2015.

C. P. Sentner, I. J. Hoogeveen, and D. A. Weinstein, Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome, J Inherit Metab Dis, vol.39, pp.697-704, 2016.

T. G. Derks and G. P. Smit, Dietary management in glycogen storage disease type III: what is the evidence?, J Inherit Metab Dis, vol.38, pp.545-550, 2015.

A. Brambilla, S. Mannarino, and R. Pretese, Improvement of cardiomyopathy after high-fat diet in two siblings with glycogen storage disease type III, JIMD Rep, vol.17, pp.91-95, 2014.

A. I. Dagli, R. T. Zori, and H. Mccune, Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet, J Inherit Metab Dis, vol.32, issue.1, pp.103-106, 2009.

C. P. Sentner, K. Caliskan, and W. B. Vletter, Heart failure due to severe hypertrophic cardiomyopathy reversed by low calorie, high protein dietary adjustments in a glycogen storage disease type IIIa patient, JIMD Rep, vol.5, pp.13-16, 2012.

V. Valayannopoulos, F. Bajolle, and J. B. Arnoux, Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet, Pediatr Res, vol.70, pp.638-641, 2011.

E. Demo, D. Frush, and M. Gottfried, Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?, J Hepatol, vol.46, pp.492-498, 2007.

L. H. Oterdoom, K. E. Verweij, and K. Biermann, Hepatocellular adenomas and carcinoma in asymptomatic, non-cirrhotic type III glycogen storage disease, J Gastrointestin Liver Dis, vol.24, pp.515-518, 2015.

N. Pursell, J. Gierut, and W. Zhou, Inhibition of glycogen synthase II with RNAi prevents liver injury in mouse models of glycogen storage diseases, Mol Ther, vol.26, pp.1771-1782, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02339568

V. Decostre, P. Laforet, D. Antonio, and M. , Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa, Mol Genet Metab, vol.122, pp.108-116, 2017.

V. Decostre, P. Laforet, and A. Nadaj-pakleza, Cross-sectional retrospective study of muscle function in patients with glycogen storage disease type III, Neuromuscul Disord, vol.26, pp.584-592, 2016.

N. Preisler, P. Laforet, and K. L. Madsen, Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III, Neurology, vol.84, pp.1767-1771, 2015.

N. Preisler, A. Pradel, and E. Husu, Exercise intolerance in glycogen storage disease type III: weakness or energy deficiency?, Mol Genet Metab, vol.109, pp.14-20, 2013.

D. Matern, T. E. Starzl, and W. Arnaout, Liver transplantation for glycogen storage disease types I, III, and IV, Eur J Pediatr, vol.158, issue.2, pp.43-48, 1999.

S. J. Boers, G. Visser, and P. G. Smit, Liver transplantation in glycogen storage disease type I, Orphanet J Rare Dis, vol.9, p.47, 2014.

E. D. Brooks, D. J. Landau, and J. I. Everitt, Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy, J Inherit Metab Dis, vol.41, pp.965-976, 2018.

D. D. Koeberl, B. D. Sun, and T. V. Damodaran, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia, Gene Ther, vol.13, pp.1281-1289, 2006.

Y. Kondo, H. Usui, and M. Ishige-wada, Liver cirrhosis treated by living donor liver transplantation in a patient with AGL mutation c.2607-2610delATTC and c.1672dupA, Clin Chim Acta, vol.424, pp.19-21, 2013.

M. Zobeiri, Liver transplantation in a myopathic patient with glycogen storage disease type IIIa and decompensated cirrhosis, Int J Organ Transplant Med, vol.8, pp.217-220, 2017.

P. Vidal, S. Pagliarani, and P. Colella, Rescue of GSDIII phenotype with gene transfer requires liver-and muscle-targeted GDE expression, Mol Ther, vol.26, pp.890-901, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02332988

J. R. Mendell, S. Al-zaidy, and R. Shell, Single-dose gene-replacement therapy for spinal muscular atrophy, N Engl J Med, vol.377, pp.1713-1722, 2017.

A. K. Pickar and C. A. Gersbach, Gene therapies for hemophilia hit the mark in clinical trials, Nat Med, vol.24, pp.121-122, 2018.

J. Bennett, J. Wellman, and K. A. Marshall, Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial, Lancet, vol.388, pp.661-672, 2016.

P. Colella, G. Ronzitti, and F. Mingozzi, Emerging issues in AAV-mediated in vivo gene therapy, Mol Ther Methods Clin Dev, vol.8, pp.87-104, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01812088

C. H. Miao, K. Ohashi, and G. A. Patijn, Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro, Mol Ther, vol.1, pp.522-532, 2000.

H. Nakai, E. Montini, and S. Fuess, AAV serotype 2 vectors preferentially integrate into active genes in mice, Nat Genet, vol.34, pp.297-302, 2003.

B. Crane, X. Luo, and A. Demaster, Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia, Gene Ther, vol.19, pp.443-452, 2012.

A. Zingone, H. Hiraiwa, and C. J. Pan, Correction of glycogen storage disease type 1a in a mouse model by gene therapy, J Biol Chem, vol.275, pp.828-832, 2000.

D. D. Koeberl, B. Sun, and A. Bird, Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia, Mol Ther, vol.15, pp.1253-1258, 2007.

W. H. Yiu, C. J. Pan, and M. Allamarvdasht, Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice, Gene Ther, vol.14, pp.219-226, 2007.

J. Clar, E. Mutel, and B. Gri, Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice, Hum Mol Genet, vol.24, pp.2287-2296, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01350897

A. Grinshpun, R. Condiotti, and S. N. Waddington, Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector, Mol Ther, vol.18, pp.1592-1598, 2010.

B. I. Raju, E. Leyvi, and R. Seip, Enhanced gene expression of systemically administered plasmid DNA in the liver with therapeutic ultrasound and microbubbles, IEEE Trans Ultrason Ferroelectr Freq Control, vol.60, pp.88-96, 2013.

L. Jiang, P. Berraondo, and D. Jerico, Systemic messenger RNA as an etiological treatment for acute intermittent porphyria, Nat Med, vol.24, pp.1899-1909, 2018.

D. S. Roseman, T. Khan, and F. Rajas, G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a, Mol Ther, vol.26, pp.814-821, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02379178

R. N. Aravalli, J. D. Belcher, and C. J. Steer, Liver-targeted gene therapy: approaches and challenges, Liver Transpl, vol.21, pp.718-737, 2015.

A. M. Keeler, M. K. Elmallah, and T. R. Flotte, Gene therapy 2017: progress and future directions, Clin Transl Sci, vol.10, pp.242-248, 2017.

F. Rajas, J. Clar, and A. Gautier-stein, Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease, J Inherit Metab Dis, vol.38, pp.521-527, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01350960

E. Mutel, A. Abdul-wahed, and N. Ramamonjisoa, Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas, J Hepatol, vol.54, pp.529-537, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00575314

R. M. Beaty, M. Jackson, and D. Peterson, Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adenoassociated virus (AAV) vectors, Gene Ther, vol.9, pp.1015-1022, 2002.

G. Y. Kim, Y. M. Lee, and J. H. Kwon, Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-alpha activity restored are at risk of developing hepatic tumors, Mol Genet Metab, vol.120, pp.229-234, 2017.

Y. M. Lee, H. S. Jun, and C. J. Pan, Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy, Hepatology, vol.56, pp.1719-1729, 2012.

J. H. Kwon, Y. M. Lee, and J. H. Cho, Liver-directed gene therapy for murine glycogen storage disease type Ib, Hum Mol Genet, vol.26, pp.4395-4405, 2017.

W. H. Yiu, C. J. Pan, and P. A. Mead, Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice, J Hepatol, vol.51, pp.909-917, 2009.

D. D. Koeberl, C. Pinto, and B. Sun, AAV vectormediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia, Mol Ther, vol.16, pp.665-672, 2008.

A. Demaster, X. Luo, and S. Curtis, Long-term efficacy following readministration of an adenoassociated virus vector in dogs with glycogen storage disease type Ia, Hum Gene Ther, vol.23, pp.407-418, 2012.

Y. M. Lee, T. J. Conlon, and A. Specht, Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia, J Inherit Metab Dis, vol.41, pp.977-984, 2018.

D. A. Weinstein, C. E. Correia, and T. Conlon, Adenoassociated virus-mediated correction of a canine model of glycogen storage disease type Ia, Hum Gene Ther, vol.21, pp.903-910, 2010.

A. Ghosh, M. Allamarvdasht, and C. J. Pan, Longterm correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer, Gene Ther, vol.13, pp.321-329, 2006.

D. M. Mccarty, Self-complementary AAV vectors; advances and applications, Mol Ther, vol.16, pp.1648-1656, 2008.

D. M. Mccarty, P. E. Monahan, and R. J. Samulski, Selfcomplementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis, Gene Ther, vol.8, pp.1248-1254, 2001.

X. Luo, G. Hall, and S. Li, Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector

, Mol Ther, vol.19, pp.1961-1970, 2011.

W. H. Yiu, Y. M. Lee, and W. T. Peng, Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy, Mol Ther, vol.18, pp.1076-1084, 2010.

G. Y. Kim, J. H. Kwon, and J. H. Cho, Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy, Hum Mol Genet, vol.26, pp.1890-1899, 2017.

Y. M. Lee, G. Y. Kim, and C. J. Pan, Minimal hepatic glucose-6-phosphatase-alpha activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia, Mol Genet Metab Rep, vol.3, pp.28-32, 2015.

E. D. Brooks, P. S. Kishnani, D. Koeberl, and . Lee, Letter to the Editors: concerning ''Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia, J Inherit Metab Dis, vol.41, pp.913-914, 2018.

Y. Lee, J. Y. Chou, and D. A. Weinstein, Response letter, J Inherit Metab Dis, vol.41, p.915, 2018.

G. Ronzitti and F. Mingozzi, Combination therapy is the new gene therapy?, Mol Ther, vol.26, pp.12-14, 2018.

D. Weinstein, A. Ahmad, and C. Lee, Positive cohort 1 results from the Phase 1/2 trial with AAV8-mediated liver-directed gene therapy in adults with Glycogen storage disease type Ia, ASGCT 22nd Annual Meeting. (Washington), vol.4, pp.1-465, 2019.

A. C. Nathwani, E. G. Tuddenham, and S. Rangarajan, Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N Engl J Med, vol.365, pp.2357-2365, 2011.

E. D. Brooks, H. Yi, and S. L. Austin, Natural progression of canine glycogen storage disease type IIIa, Comp Med, vol.66, pp.41-51, 2016.

H. Yi, B. L. Thurberg, and S. Curtis, Characterization of a canine model of glycogen storage disease type IIIa, Dis Model Mech, vol.5, pp.804-811, 2012.

K. M. Liu, J. Y. Wu, and Y. T. Chen, Mouse model of glycogen storage disease type III, Mol Genet Metab, vol.111, pp.467-476, 2014.

S. Pagliarani, S. Lucchiari, and G. Ulzi, Glycogen storage disease type III: a novel Agl knockout mouse model, Biochim Biophys Acta, vol.1842, pp.2318-2328, 2014.

B. Sun, K. Fredrickson, and S. Austin, Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III, Mol Genet Metab, vol.108, pp.145-147, 2013.

F. Puzzo, P. Colella, and M. G. Biferi, Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase, Sci Transl Med, vol.9, p.6375, 2017.

G. P. Niemeyer, R. W. Herzog, and J. Mount, Longterm correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood, vol.113, pp.797-806, 2009.

A. C. Nathwani, U. M. Reiss, and E. G. Tuddenham, Long-term safety and efficacy of factor IX gene therapy in hemophilia B, N Engl J Med, vol.371, pp.1994-2004, 2014.

H. R. Kang, L. Waskowicz, and A. M. Seifts, Bezafibrate enhances AAV vector-mediated genome editing in glycogen storage disease type Ia, Mol Ther Methods Clin Dev, vol.13, pp.265-273, 2019.

D. J. Landau, E. D. Brooks, and P. Perez-pinera, In vivo zinc finger nuclease-mediated targeted integration of a glucose-6-phosphatase transgene promotes survival in mice with glycogen storage disease type IA, Mol Ther, vol.24, pp.697-706, 2016.

H. Kang, . Brook, and D. Courtney, Genome editing with CRISPR/Cas9 in a GSDIa canine model, ASGCT 22nd Annual Meeting. (Washington), vol.4, pp.1-465, 2019.

P. Berraondo, P. Martini, and M. A. Avila, Messenger RNA therapy for rare genetic metabolic diseases, Gut, vol.68, pp.1323-1330, 2019.

J. Cao, M. Silva, and P. E. , mRNA Therapy for the treatment of glycogen storage disease type 1a (GSD1a), ASGCT 22nd Annual Meeting. (Washington), vol.4, pp.1-465, 2019.

L. R. Waskowicz, J. Zhou, and D. J. Landau, Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia, Hum Mol Genet, vol.28, pp.143-154, 2019.

P. Colella, P. Sellier, C. Verdera, and H. , AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate pompe mice, Mol Ther Methods Clin Dev, vol.12, pp.85-101, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02087558

A. Patel, J. Zhao, and D. Duan, Design of AAV vectors for delivery of large or multiple transgenes, Methods Mol Biol, pp.19-33, 1950.